Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: MYL12A

Summary for MYL12A

Gene information	Gene symbol	MYL12A
	Ensembl ID	ENSG00000101608
	Entrez ID	10627
	Gene name	myosin light chain 12A
	Synonyms	MLCB\|MRCL3\|MRLC3\|MYL2B
	Gene type	protein_coding
	UniProtAcc	P19105

Top

Dataset with differentially expressed gene: MYL12A

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	1.12893	7.05e-30
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.928709	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.318552	1.27e-11
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.282341	8.24e-43
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.253235	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.298981	2.09e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.298915	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.271517	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.566724	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.321331	1.58e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.361474	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.497186	6.88e-26
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.509646	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.279947	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	-0.37154	4.78e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.333076	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.435783	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.266414	1.56e-12
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.271874	3.06e-10
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.540846	1.42e-09
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.309207	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.256878	4.97e-04
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.267466	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.786066	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.692788	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.267952	9.16e-32
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.38986	3.67e-18
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-0.415335	9.85e-14
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.285409	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.332682	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.318112	3.67e-10
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	0.345017	6.17e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.390897	1.61e-14
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.32525	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	1.17951	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.958015	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.53605	1.98e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	1.47396	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	0.550228	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.671736	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.41231	3.12e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.37804	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.302936	9.15e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.283328	1.68e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	0.297688	2.73e-02
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	0.403148	3.46e-02
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.906715	1.31e-41
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.47313	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.333492	5.69e-15
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.649974	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.600532	7.01e-45
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.625199	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.14692	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.635636	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.315619	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.687447	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.431862	0.00e+00

Top

Expression of MYL12A in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MYL12A

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating MYL12A

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
MYL12A	hsa-miR-622	95.3343	NM_001303047
MYL12A	hsa-miR-4430	94.136	NM_001303048
MYL12A	hsa-miR-3652	94.136	NM_001303048
MYL12A	hsa-miR-146a-3p	93.4541	NM_001303048
MYL12A	hsa-miR-6842-3p	93.2855	NM_001303048
MYL12A	hsa-miR-3920	92.641	NM_001303047
MYL12A	hsa-miR-561-3p	89.5999	NM_001303048
MYL12A	hsa-miR-6862-5p	89.0199	NM_001303047
MYL12A	hsa-miR-548aj-5p	86.3115	NM_001303047
MYL12A	hsa-miR-548g-5p	86.3115	NM_001303047
MYL12A	hsa-miR-548f-5p	86.3115	NM_001303047
MYL12A	hsa-miR-548x-5p	86.3115	NM_001303047
MYL12A	hsa-miR-889-5p	86.2076	NM_001303048
MYL12A	hsa-miR-4253	85.7745	NM_001303047
MYL12A	hsa-miR-340-5p	85.4883	NM_001303048
MYL12A	hsa-miR-4723-5p	83.8429	NM_001303048
MYL12A	hsa-miR-5698	83.8429	NM_001303048
MYL12A	hsa-miR-6870-5p	83.8429	NM_001303048
MYL12A	hsa-miR-7111-5p	83.8429	NM_001303048
MYL12A	hsa-miR-29a-5p	81.8484	NM_001303047
MYL12A	hsa-miR-4492	80.8212	NM_001303048

Page: 1

Top

Motifs and transcription factors (TFs) regulating MYL12A

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
MYL12A	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
MYL12A	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
MYL12A	metacluster_166.4	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).
MYL12A	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
MYL12A	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
MYL12A	swissregulon__hs__ELF2	ELF2 (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP_repr	ELK1; TBX21 (directAnnotation).
MYL12A	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
MYL12A	hdpi__ETV4	ETV4 (directAnnotation).
MYL12A	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
MYL12A	cisbp__M02645	ETS1 (directAnnotation).
MYL12A	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr	ETV2; HOXA2 (directAnnotation).
MYL12A	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
MYL12A	taipale_tf_pairs__ETV5_EOMES_TNRCACCGGAWN_CAP	EOMES; ETV5 (directAnnotation).
MYL12A	metacluster_166.2	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).
MYL12A	taipale_tf_pairs__FOXO1_ELK1_TGTTGCCGGANNN_CAP	ELK1; FOXO1 (directAnnotation).
MYL12A	taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP	ELK3; HOXB2 (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_HOXA3_RSCGGTAATKR_CAP_repr	ELK1; HOXA3 (directAnnotation).
MYL12A	jaspar__MA1483.2	ELF2 (directAnnotation).
MYL12A	cisbp__M00808	MYPOP (inferredBy_Orthology).
MYL12A	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_EOMES_TNRCACCGGAAGN_CAP	ELK1; EOMES (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
MYL12A	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
MYL12A	cisbp__M08198	ELF1 (directAnnotation).
MYL12A	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
MYL12A	metacluster_198.7	AHR; ZBTB14; ZBTB14; ZBTB14 (directAnnotation).
MYL12A	hdpi__TP73	TP73 (directAnnotation).
MYL12A	taipale_tf_pairs__ERF_HES7_NCCGGAANNNNNNCACGYGNN_CAP_repr	ERF; HES7 (directAnnotation).
MYL12A	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
MYL12A	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
MYL12A	jaspar__MA1957.1	ELK1 (directAnnotation).
MYL12A	kznf__ZNF777_Imbeault2017_RP_ChIP-seq	ZNF777 (directAnnotation).
MYL12A	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
MYL12A	metacluster_67.2	ZNF501 (directAnnotation). ACAA1; E2F2; E2F2; E2F3; E2F3; FOXN4 (inferredBy_Orthology).
MYL12A	metacluster_3.14	WT1; WT1 (directAnnotation).
MYL12A	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
MYL12A	transfac_pro__M04617	ZBTB7A (directAnnotation).
MYL12A	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
MYL12A	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
MYL12A	taipale_cyt_meth__E2F2_NCGCGCGCGCM_eDBD_meth	E2F2 (directAnnotation).
MYL12A	transfac_pro__M07387	ZBTB7A (directAnnotation).
MYL12A	transfac_pro__M07436	WT1 (directAnnotation).
MYL12A	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
MYL12A	transfac_pro__M00716	ZBTB14 (directAnnotation).
MYL12A	hdpi__HIP2	UBE2K (directAnnotation).
MYL12A	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	GCM1; SPDEF (directAnnotation).
MYL12A	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
MYL12A	transfac_pro__M04893	TAF1 (directAnnotation).

Page: 1 2 3 4 5 6 7

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
MYL12A	"4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID"	DB08378	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."